Rongbin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rongbin Wang has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Jacques Neefjes
Department of Cell and Chemical Biology, ONCODE Institute, Leiden University Medical Center
3 shared publications - Mikko Metsä-Ketelä
Department of Life Technologies University of Turku Turku Finland
3 shared publications - Stephen Eric Nybo
Department of Pharmaceutical Sciences College of Pharmacy Ferris State University Big Rapids Michigan USA
3 shared publications Courtney L. Brown
Department of Pharmaceutical Sciences College of Pharmacy Ferris State University Big Rapids Michigan USA
2 shared publicationsHeli Tirkkonen
Department of Life Technologies University of Turku Turku Finland
2 shared publicationsIsaline Fagon
Chemistry and Chemical Engineering Department SIGMA Clermont Aubière France
2 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (45) , e1050964
Complete Pathway Refactoring and Combinatorial Biosynthesis of Anthracyclines for Modulation of Histone Eviction and DNA Damage Bioactivities
Anthracyclines including doxorubicin are cornerstone chemotherapeutic agents with high cytotoxic potency, but their use in cancer treatment is limited by irreversible dose‐dependent cardiotoxicity. Recent investigations indicate that cardiotoxicity‐free anthracyclines may be achieved through uncoupling DNA damage from chromatin damage. However, semi‐synthetic derivatization is complicated by anthracycline structural complexity. Here, we report a modular synthetic biology platform for the complete refactoring and combinatorial biosynthesis of anthracyclines in Streptomyces coelicolor M1152Δ matAB . Using standardized synthetic DNA parts, we refactored three full biosynthetic pathways of nogalamycin (38 genes), doxorubicin (31 genes), and aclacinomycin (31 genes). The pathways were organized into four functional modules (aglycone biosynthesis, TDP‐carbohydrate formation, glycosylation, and tailoring reactions) to facilitate efficient reconstruction. The modular design facilitated streamlined combinatorial biosynthesis yielding 16 derivatives, including 13 novel analogs. Bioactivity profiling across human cancer cell lines identified six potent congeners. Their cytotoxicity correlated with in vitro DNA binding affinities. Two hit molecules harbored desired bioactivity profiles promoting histone eviction at a faster rate than doxorubicin, without causing DNA double strand breaks. Our approach highlights the power of synthetic biology in rational natural product engineering and provides a scalable strategy for exploring new and improved anthracycline anti‐cancer agents.
- 23 September 2026
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (45) , e1050964
Open AccessComplete Pathway Refactoring and Combinatorial Biosynthesis of Anthracyclines for Modulation of Histone Eviction and DNA Damage Bioactivities
Anthracyclines including doxorubicin are cornerstone chemotherapeutic agents with high cytotoxic potency, but their use in cancer treatment is limited by irreversible dose‐dependent cardiotoxicity. Recent investigations indicate that cardiotoxicity‐free anthracyclines may be achieved through uncoupling DNA damage from chromatin damage. However, semi‐synthetic derivatization is complicated by anthracycline structural complexity. Here, we report a modular synthetic biology platform for the complete refactoring and combinatorial biosynthesis of anthracyclines in Streptomyces coelicolor M1152Δ matAB . Using standardized synthetic DNA parts, we refactored three full biosynthetic pathways of nogalamycin (38 genes), doxorubicin (31 genes), and aclacinomycin (31 genes). The pathways were organized into four functional modules (aglycone biosynthesis, TDP‐carbohydrate formation, glycosylation, and tailoring reactions) to facilitate efficient reconstruction. The modular design facilitated streamlined combinatorial biosynthesis yielding 16 derivatives, including 13 novel analogs. Bioactivity profiling across human cancer cell lines identified six potent congeners. Their cytotoxicity correlated with in vitro DNA binding affinities. Two hit molecules harbored desired bioactivity profiles promoting histone eviction at a faster rate than doxorubicin, without causing DNA double strand breaks. Our approach highlights the power of synthetic biology in rational natural product engineering and provides a scalable strategy for exploring new and improved anthracycline anti‐cancer agents.
- Open Access
- 23 September 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (45) , e1050964
Complete Pathway Refactoring and Combinatorial Biosynthesis of Anthracyclines for Modulation of Histone Eviction and DNA Damage Bioactivities
Anthracyclines including doxorubicin are cornerstone chemotherapeutic agents with high cytotoxic potency, but their use in cancer treatment is limited by irreversible dose‐dependent cardiotoxicity. Recent investigations indicate that cardiotoxicity‐free anthracyclines may be achieved through uncoupling DNA damage from chromatin damage. However, semi‐synthetic derivatization is complicated by anthracycline structural complexity. Here, we report a modular synthetic biology platform for the complete refactoring and combinatorial biosynthesis of anthracyclines in Streptomyces coelicolor M1152Δ matAB . Using standardized synthetic DNA parts, we refactored three full biosynthetic pathways of nogalamycin (38 genes), doxorubicin (31 genes), and aclacinomycin (31 genes). The pathways were organized into four functional modules (aglycone biosynthesis, TDP‐carbohydrate formation, glycosylation, and tailoring reactions) to facilitate efficient reconstruction. The modular design facilitated streamlined combinatorial biosynthesis yielding 16 derivatives, including 13 novel analogs. Bioactivity profiling across human cancer cell lines identified six potent congeners. Their cytotoxicity correlated with in vitro DNA binding affinities. Two hit molecules harbored desired bioactivity profiles promoting histone eviction at a faster rate than doxorubicin, without causing DNA double strand breaks. Our approach highlights the power of synthetic biology in rational natural product engineering and provides a scalable strategy for exploring new and improved anthracycline anti‐cancer agents.
- 23 September 2026
- Published by Wiley in Angewandte Chemie
- Vol. 138 (45) , e1050964
Open AccessComplete Pathway Refactoring and Combinatorial Biosynthesis of Anthracyclines for Modulation of Histone Eviction and DNA Damage Bioactivities
Anthracyclines including doxorubicin are cornerstone chemotherapeutic agents with high cytotoxic potency, but their use in cancer treatment is limited by irreversible dose‐dependent cardiotoxicity. Recent investigations indicate that cardiotoxicity‐free anthracyclines may be achieved through uncoupling DNA damage from chromatin damage. However, semi‐synthetic derivatization is complicated by anthracycline structural complexity. Here, we report a modular synthetic biology platform for the complete refactoring and combinatorial biosynthesis of anthracyclines in Streptomyces coelicolor M1152Δ matAB . Using standardized synthetic DNA parts, we refactored three full biosynthetic pathways of nogalamycin (38 genes), doxorubicin (31 genes), and aclacinomycin (31 genes). The pathways were organized into four functional modules (aglycone biosynthesis, TDP‐carbohydrate formation, glycosylation, and tailoring reactions) to facilitate efficient reconstruction. The modular design facilitated streamlined combinatorial biosynthesis yielding 16 derivatives, including 13 novel analogs. Bioactivity profiling across human cancer cell lines identified six potent congeners. Their cytotoxicity correlated with in vitro DNA binding affinities. Two hit molecules harbored desired bioactivity profiles promoting histone eviction at a faster rate than doxorubicin, without causing DNA double strand breaks. Our approach highlights the power of synthetic biology in rational natural product engineering and provides a scalable strategy for exploring new and improved anthracycline anti‐cancer agents.
- Open Access
- 4 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Metabolic engineering of doxorubicin biosynthesis through P450-redox partner optimization and structural analysis of DoxA
Doxorubicin, a widely used chemotherapy drug, is produced by Streptomyces peucetius ATCC27952. The biosynthesis relies on the cytochrome P450 monooxygenase DoxA, which catalyzes three consecutive late-stage oxidation steps. However, conversion from daunorubicin to doxorubicin is inefficient, necessitating semi-synthetic industrial manufacturing. Here, we address key limitations in DoxA catalysis. We identify the natural redox partners ferredoxin Fdx4 and ferredoxin reductase FdR3 by transcriptomic analysis. We discovered the vicinal oxygen chelate family protein DnrV to prevent product inhibition by binding doxorubicin. Structural analysis of DoxA and density functional theory (DFT) calculations reveal that inefficient C14 hydroxylation results from the unfavorable anti-conformation of the methyl ketone side chain of daunorubicin. We harness these advances for rational strain engineering, leading to an 180% increase in doxorubicin yields and an improved production profile. This study provides singular insights into enzymatic constraints in anthracycline biosynthesis and facilitates cost-effective manufacturing to meet the growing global demand for doxorubicin.
- 4 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMetabolic engineering of doxorubicin biosynthesis through P450-redox partner optimization and structural analysis of DoxA
Doxorubicin, a widely used chemotherapy drug, is produced by Streptomyces peucetius ATCC27952. The biosynthesis relies on the cytochrome P450 monooxygenase DoxA, which catalyzes three consecutive late-stage oxidation steps. However, conversion from daunorubicin to doxorubicin is inefficient, necessitating semi-synthetic industrial manufacturing. Here, we address key limitations in DoxA catalysis. We identify the natural redox partners ferredoxin Fdx4 and ferredoxin reductase FdR3 by transcriptomic analysis. We discovered the vicinal oxygen chelate family protein DnrV to prevent product inhibition by binding doxorubicin. Structural analysis of DoxA and density functional theory (DFT) calculations reveal that inefficient C14 hydroxylation results from the unfavorable anti-conformation of the methyl ketone side chain of daunorubicin. We harness these advances for rational strain engineering, leading to an 180% increase in doxorubicin yields and an improved production profile. This study provides singular insights into enzymatic constraints in anthracycline biosynthesis and facilitates cost-effective manufacturing to meet the growing global demand for doxorubicin.
- 20 August 2020
- Published by Wiley in Journal of Chemical Technology & Biotechnology
- Vol. 96 (2) , 412-422
MAPK/HOG signaling pathway induced stress‐responsive damage repair is a mechanism for Pichia pastoris to survive from hyperosmotic stress
BACKGROUND: MAPK/HOG signaling pathway plays a key role in the response of yeast to external hyperosmotic stress. Over the past few decades, the regulation mechanism for this pathway in the robust yeast, Saccharomyces cerevisiae, has been elucidated. However, the weak ability of the biotechnical workhorse, Pichia pastoris, in surviving hyperosmotic stress suggests a unique regulatory mechanism needing further investigation.RESULT: Here, we identified crucial genes in the MAPK/HOG pathway of P. pastoris and investigated their effects on cell growing in osmotically stressed environments by knocking out these genes using a novel CRISPR/Cas9 system. Using real‐time polymerase chain reaction (RT‐PCR) and yeast two‐hybrid assay, transcription factors Hot1, Msn4 and Sko1 were demonstrated to be regulated by Pbs2 and Hog1 either at mRNA or protein level. We also examined the subcellular localization of these transcription factors, reflecting their translocation between cytoplasm and nucleus. The transcriptions of putative osmo‐responsive genes were then studied by RT‐PCR. We found the induction of glycerol‐related genes, such as GT1 and GPD1, was marginal when cells experienced high osmolarity. The ability of P. pastoris to increase intracellular glycerol level was determined and found to be much weaker than that in S. cerevisiae. By contrast, stress‐induced damage repair genes, including CTT1 and HSP12, were dramatically increased.CONCLUSION: We conclude that P. pastoris could barely balance hyperosmotic stress by increasing intracellular glycerol concentrations, and stress‐induced damage repair is still an important mechanism for P. pastoris survival under hyperosmotic stress. This study demonstrates a description of the MAPK/HOG pathway in P. pastoris and provides a trigger for improving its robustness. © 2020 Society of Chemical Industry (SCI)
- 20 August 2020
- Published by Wiley in Journal of Chemical Technology & Biotechnology
- Vol. 96 (2) , 412-422
MAPK/HOG signaling pathway induced stress‐responsive damage repair is a mechanism for Pichia pastoris to survive from hyperosmotic stress
BACKGROUND: MAPK/HOG signaling pathway plays a key role in the response of yeast to external hyperosmotic stress. Over the past few decades, the regulation mechanism for this pathway in the robust yeast, Saccharomyces cerevisiae, has been elucidated. However, the weak ability of the biotechnical workhorse, Pichia pastoris, in surviving hyperosmotic stress suggests a unique regulatory mechanism needing further investigation.RESULT: Here, we identified crucial genes in the MAPK/HOG pathway of P. pastoris and investigated their effects on cell growing in osmotically stressed environments by knocking out these genes using a novel CRISPR/Cas9 system. Using real‐time polymerase chain reaction (RT‐PCR) and yeast two‐hybrid assay, transcription factors Hot1, Msn4 and Sko1 were demonstrated to be regulated by Pbs2 and Hog1 either at mRNA or protein level. We also examined the subcellular localization of these transcription factors, reflecting their translocation between cytoplasm and nucleus. The transcriptions of putative osmo‐responsive genes were then studied by RT‐PCR. We found the induction of glycerol‐related genes, such as GT1 and GPD1, was marginal when cells experienced high osmolarity. The ability of P. pastoris to increase intracellular glycerol level was determined and found to be much weaker than that in S. cerevisiae. By contrast, stress‐induced damage repair genes, including CTT1 and HSP12, were dramatically increased.CONCLUSION: We conclude that P. pastoris could barely balance hyperosmotic stress by increasing intracellular glycerol concentrations, and stress‐induced damage repair is still an important mechanism for P. pastoris survival under hyperosmotic stress. This study demonstrates a description of the MAPK/HOG pathway in P. pastoris and provides a trigger for improving its robustness. © 2020 Society of Chemical Industry (SCI)
- 1 June 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (11) , 1282-1290
Discovery of an EGFR tyrosine kinase inhibitor from Ilex latifolia in breast cancer therapy
- 1 June 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (11) , 1282-1290
Discovery of an EGFR tyrosine kinase inhibitor from Ilex latifolia in breast cancer therapy
- 30 July 2008
- Published by Springer Nature in Medical Oncology
- Vol. 26 (2) , 117-123
Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry
Aim To investigate whether the presence of CD147 and MMP-2 in cancerous gallbladder tissues might help us to predict the patients’ prognosis. Methods Tissue samples from 168 patients with gallbladder carcinomas and 37 patients with chronic cholecystitis were stained with anti-CD147 and anti-MMP-2 antibodies for immunohistochemical analysis. Then, the association of their expression with clinicopathologic characteristics and 108 patients’ prognosis was analyzed. Results CD147 and MMP-2 were detected mainly in cancerous tissues, but also expressed in some chronic cholecystitis patients. Out of 168 patients with gallbladder carcinoma 121 (72.02%) and 136 (80.95%) patients showed CD147 and MMP-2 positive expression, whereas the 37 patients with chronic cholecystitis only 5 (13.51%) and 3 (8.11%) patients expressed them, respectively. Pathologic findings demonstrated that the intensity of CD147 and MMP-2 staining in cancerous tissues was associated significantly with histological types (P = 0.03), distant metastasis (P < 0.01), and Nevin stages (P = 0.02) of gallbladder carcinomas. Using a proportional hazard model, the survival rate of the patients with CD147+/MMP-2+ expression was the lowest (P < 0.01), and including information on CD147 and MMP-2 staining patterns within cancerous tissues along with clinical cancer staging may improve the accuracy of predicting patients’ prognosis. Conclusion The results suggest that the expression of CD147 and MMP-2 may be an important feature of gallbladder carcinomas. The detection of these two markers combined with cancerous staging may increase the ability of investigators to predict the prognosis of patients with gallbladder carcinomas.
- 30 July 2008
- Published by Springer Nature in Medical Oncology
- Vol. 26 (2) , 117-123
Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry
Aim To investigate whether the presence of CD147 and MMP-2 in cancerous gallbladder tissues might help us to predict the patients’ prognosis. Methods Tissue samples from 168 patients with gallbladder carcinomas and 37 patients with chronic cholecystitis were stained with anti-CD147 and anti-MMP-2 antibodies for immunohistochemical analysis. Then, the association of their expression with clinicopathologic characteristics and 108 patients’ prognosis was analyzed. Results CD147 and MMP-2 were detected mainly in cancerous tissues, but also expressed in some chronic cholecystitis patients. Out of 168 patients with gallbladder carcinoma 121 (72.02%) and 136 (80.95%) patients showed CD147 and MMP-2 positive expression, whereas the 37 patients with chronic cholecystitis only 5 (13.51%) and 3 (8.11%) patients expressed them, respectively. Pathologic findings demonstrated that the intensity of CD147 and MMP-2 staining in cancerous tissues was associated significantly with histological types (P = 0.03), distant metastasis (P < 0.01), and Nevin stages (P = 0.02) of gallbladder carcinomas. Using a proportional hazard model, the survival rate of the patients with CD147+/MMP-2+ expression was the lowest (P < 0.01), and including information on CD147 and MMP-2 staining patterns within cancerous tissues along with clinical cancer staging may improve the accuracy of predicting patients’ prognosis. Conclusion The results suggest that the expression of CD147 and MMP-2 may be an important feature of gallbladder carcinomas. The detection of these two markers combined with cancerous staging may increase the ability of investigators to predict the prognosis of patients with gallbladder carcinomas.